<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Genet</journal-id><journal-title>BMC Medical Genetics</journal-title><issn pub-type="epub">1471-2350</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2350-8-33</article-id><article-id pub-id-type="pmid">17565662</article-id><article-id pub-id-type="doi">10.1186/1471-2350-8-33</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Lack of association between the chemokine receptor 5 polymorphism CCR5delta32 in rheumatoid arthritis and juvenile idiopathic arthritis</article-title></title-group><contrib-group><contrib id="A1" equal-contrib="yes" contrib-type="author"><name><surname>Lindner</surname><given-names>Ewald</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Ewald.Lindner@student.uibk.ac.at</email></contrib><contrib id="A2" equal-contrib="yes" contrib-type="author"><name><surname>Nordang</surname><given-names>Gry BN</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>g.b.namlos@medisin.uio.no</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Melum</surname><given-names>Espen</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>espen.melum@medisin.uio.no</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Flat&#x000f8;</surname><given-names>Berit</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>berit.flato@rikshospitalet.no</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Selvaag</surname><given-names>Anne Marit</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>aselvaag@ulrik.uio.no</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Thorsby</surname><given-names>Erik</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>erik.thorsby@medisin.uio.no</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Kvien</surname><given-names>Tore K</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>t.k.kvien@medisin.uio.no</email></contrib><contrib id="A8" contrib-type="author"><name><surname>F&#x000f8;rre</surname><given-names>&#x000d8;ystein T</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>o.t.forre@medisin.uio.no</email></contrib><contrib id="A9" corresp="yes" contrib-type="author"><name><surname>Lie</surname><given-names>Benedicte A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>b.a.lie@medisin.uio.no</email></contrib></contrib-group><aff id="I1"><label>1</label>Institute of Immunology, Rikshospitalet-Radiumhospitalet Medical Center, 0027 Oslo, Norway</aff><aff id="I2"><label>2</label>Department of Rheumatology, Rikshospitalet-Radiumhospitalet Medical Center, 0027 Oslo, Norway</aff><aff id="I3"><label>3</label>Department of Rheumatology, Diakonhjemmet Hospital, N-0319 Oslo, Norway</aff><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>12</day><month>6</month><year>2007</year></pub-date><volume>8</volume><fpage>33</fpage><lpage>33</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/8/33"/><history><date date-type="received"><day>29</day><month>11</month><year>2006</year></date><date date-type="accepted"><day>12</day><month>6</month><year>2007</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2007 Lindner et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>Lindner et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Lindner Ewald Ewald.Lindner@student.uibk.ac.at </dc:author><dc:title> Lack of association between the chemokine receptor 5 polymorphism CCR5delta32 in rheumatoid arthritis and juvenile idiopathic arthritis </dc:title><dc:date>2007</dc:date><dcterms:bibliographicCitation>BMC Medical Genetics 8(1): 33-. (2007)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2350(2007)8:1&#x0003c;33&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2350</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>The chemokine receptor CCR5 has been detected at elevated levels on synovial T cells, and a 32 bp deletion in the <italic>CCR5 </italic>gene leads to a non-functional receptor. A negative association between the <italic>CCR5&#x00394;32 </italic>and rheumatoid arthritis (RA) has been reported, although with conflicting results. In juvenile idiopathic arthritis (JIA), an association with CCR5 was recently reported. The purpose of this study was to investigate if the <italic>CCR5&#x00394;32 </italic>polymorphism is associated with RA or JIA in Norwegian cohorts.</p></sec><sec sec-type="methods"><title>Methods</title><p>853 RA patients, 524 JIA patients and 658 controls were genotyped for the <italic>CCR5&#x00394;32 </italic>polymorphism.</p></sec><sec><title>Results</title><p>The <italic>CCR5&#x00394;32 </italic>allele frequency was 11.5% in the controls vs. 10.4% in RA patients (OR = 0.90; <italic>P </italic>= 0.36) and 9.7% in JIA patients (OR = 0.85; <italic>P </italic>= 0.20). No decreased homozygosity was observed for <italic>CCR5&#x00394;32</italic>, as previously suggested.</p></sec><sec><title>Conclusion</title><p>Our data do not support an association between the <italic>CCR5&#x00394;32 </italic>allele and Norwegian RA or JIA patients. Combining our results with those from a recently published meta-analysis still provide evidence for a role for <italic>CCR5&#x00394;32 </italic>in RA, albeit substantially weaker than the effect first reported.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>In rheumatoid arthritis (RA) and juvenile idiopatic arthritis (JIA), the synovium is infiltrated with T cells and macrophages, and chemokine receptors and their ligands are involved in regulation of the inflammation [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. Chemokines regulate lymphocyte trafficking by inducing cell motility and activating adhesion molecules. The chemokine receptor CCR5 is a G-protein-coupled seven-transmembrane-receptor, and it is expressed on monocytes, macrophages, memory T-cells and dendritic cells, where it serves as a receptor for RANTES, MIP-1-&#x003b1;, MIP-1-&#x003b2; and MCP [<xref ref-type="bibr" rid="B3">3</xref>]. CCR5 has functionally been implicated in the pathogenesis of RA [<xref ref-type="bibr" rid="B2">2</xref>] and JIA [<xref ref-type="bibr" rid="B4">4</xref>]. The expression of CCR5 is increased on synovial T cells in patients with JIA [<xref ref-type="bibr" rid="B4">4</xref>] or RA [<xref ref-type="bibr" rid="B5">5</xref>].</p><p>The gene encoding CCR5 is located on chomosome 3p21.3 [<xref ref-type="bibr" rid="B6">6</xref>]. A 32 base pair deletion (<italic>CCR5&#x00394;32</italic>) in the <italic>CCR5 </italic>gene leads to a frame shift and a non-functional receptor. Homozygosity for <italic>CCR5&#x00394;32 </italic>results in a complete lack of surface expression of CCR5 [<xref ref-type="bibr" rid="B7">7</xref>]. CCR5 happens to be a co-receptor for HIV-1 on CD4+ T-cells with the consequence that <italic>CCR5&#x00394;32 </italic>homozygotes are protected against infections with HIV-1, while heterozygotes have a delay in the progression towards AIDS [<xref ref-type="bibr" rid="B8">8</xref>]. The <italic>CCR5 </italic>deletion is common among Caucasians, especially in Nordic populations [<xref ref-type="bibr" rid="B9">9</xref>], but has not been found in native Africans, American Indians or East Indian ethnic groups.</p><p>The role of <italic>CCR5&#x00394;32 </italic>has been investigated genetically in several immune-mediated diseases. In RA, a negative association of the deletion has been reported with divergent results [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B14">14</xref>], while in childhood arthritis a weak negative association has been observed in a single study [<xref ref-type="bibr" rid="B15">15</xref>]. Regarding clinical outcome, it has been reported that carriers of the <italic>CCR5&#x00394;32 </italic>allele occurred at a significantly higher frequency among patients with non-severe compared to severe disease (N = 160) [<xref ref-type="bibr" rid="B14">14</xref>], whereas a later and larger study of 438 patients did not find any association between carriage of the <italic>CCR5&#x00394;32 </italic>and milder disease severity in inflammatory polyarthritis [<xref ref-type="bibr" rid="B16">16</xref>]. A recent meta-analysis of five reports addressing the association of <italic>CCR5&#x00394;32 </italic>with susceptibility to develop RA in patients of European ancestry (1790 cases and 2717 controls), reported a significant negative association and estimated the deletion to provide disease resistance with an OR = 0.65 (95% CI [0.55&#x02013;0.77])[<xref ref-type="bibr" rid="B17">17</xref>].</p><p>The aim of our study was to investigate if there is an association between <italic>CCR5&#x00394;32 </italic>and RA in the largest individual data set studied so far, as well as to address whether <italic>CCR5&#x00394;32 </italic>is also associated with JIA, not yet extensively investigated.</p></sec><sec sec-type="methods"><title>Methods</title><p>853 RA patients, 524 JIA patients and 658 controls were included in the study. The RA patients, admitted to the Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, fulfilled the American College of Rheumatology (ACR) criteria [<xref ref-type="bibr" rid="B18">18</xref>] and the JIA patients, admitted to the Department of Rheumatology, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway, were classified according to the ILAR (International League of Associations for Rheumatology) criteria [<xref ref-type="bibr" rid="B19">19</xref>]. The control group was recruited through the Norwegian Bone Marrow Registry. All patients and controls were of Norwegian origin. The study was approved by the Norwegian Regional Ethics committee, and the participants had given their informed consent.</p><p>Whole-genome amplification was performed on genomic DNA using the Genomiphi<sup>&#x000ae; </sup>kit (GE healthcare systems, Chalfont St. Giles, UK). Amplification of fragment surrounding the deletion was performed with the dye labelled forward primer 5'-ATCACTTGGGTGGTGGCTGTGTTTGCGTCTC and the reverse primer 5'-AGTAGCAGATGACCATGACAAGCAGCGGCAG under the following conditions; denaturation at 94&#x000b0;C for 15 seconds, annealing and extension at 70&#x000b0;C for 15 seconds, 30 cycles and final extension at 70&#x000b0;C for 5 min at a Perkin Elmer 9700 thermal cycler (Applied Biosystems, Foster City, CA, USA). Fragment length was determined on an ABI3730 DNA Analyzer (Applied Biosystems) with subsequent allele calling in GeneMapper v3.7 where a 193 bp PCR product corresponded to the wild type allele and a 161 bp product represented the deletion. Part of the control material was genotyped in our previous publication [<xref ref-type="bibr" rid="B20">20</xref>].</p><p>Statistical power was calculated prior to the study using the power calculator at [<xref ref-type="bibr" rid="B21">21</xref>], assuming the frequency of 10% for the <italic>CCR5&#x00394;32 </italic>and an Odds Ratio of 0.56 (obtained from Zapico et al [<xref ref-type="bibr" rid="B14">14</xref>]). The power (at &#x003b1; = 0.05) was calculated to be 84% for the RA and 75% for the JIA data set. Allele and genotype frequencies in patients and controls were compared by the Chi-Square test, or Fischer's exact test when appropriate, using the Public Domain Software for Epidemiology and Disease Surveillance EPI Info Version 5 (Center of Disease Control, Epidemiology Program Office, Atlanta, GA, USA).</p></sec><sec><title>Results and Discussion</title><p>The genotype and allele frequencies of <italic>CCR5&#x00394;32 </italic>are summarised in Table <xref ref-type="table" rid="T1">1</xref>. The genotyping success rate was &#x0003e;95% for both the patients and control populations, and all groups were in Hardy-Weinberg equilibrium. No significant negative association was observed with the &#x00394;32 allele in either RA or JIA (Table <xref ref-type="table" rid="T1">1</xref>), and only a negligible deviation in frequency was seen between the patients and controls. Furthermore, no decreased frequency for homozygosity of &#x00394;32 was evident among the patients (0.9% in RA, 0.6% in JIA and 1.0% in controls). A revised meta-analysis, calculated by adding our results to those from the recently published meta-analysis of pooled RA cases and controls [<xref ref-type="bibr" rid="B17">17</xref>], reduced the initial published risk estimate from OR = 0.65; 95% CI [0.55&#x02013;0.77], <italic>p </italic>&#x0003c; 0.0001, to OR = 0.83; 95% CI [0.73&#x02013;0.95], <italic>p = 0.0068</italic>.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p><italic>CCR5 </italic>genotype and allele frequencies among controls, RA patients and JIA patients</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center"><bold>Controls no. (%)</bold></td><td align="center"><bold>RA no. (%)</bold></td><td align="center"><bold>OR (95% CI)</bold></td><td align="center"><bold><italic>p</italic></bold></td><td align="center"><bold>JIA no. (%)</bold></td><td align="center"><bold>OR (95% CI)</bold></td><td align="center"><bold><italic>p</italic></bold></td></tr><tr><td align="left"><bold>CCR5 genotype</bold></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></thead><tbody><tr><td align="left"><bold>&#x00394;32/&#x00394;32</bold></td><td align="center">6 (0.9)</td><td align="center">9 (1.0)</td><td align="center">1.13 (0.43&#x02013;2.98)</td><td align="center">0.81</td><td align="center">3 (0.6)</td><td align="center">0.67 (0.20&#x02013;2.31)</td><td align="center">0.53</td></tr><tr><td align="left"><bold>&#x00394;32/wt</bold></td><td align="center">136 (21.1)</td><td align="center">156 (18.7)</td><td align="center">0.86 (0.66&#x02013;1.11)</td><td align="center">0.24</td><td align="center">93 (18.1)</td><td align="center">0.83 (0.62&#x02013;1.11)</td><td align="center">0.20</td></tr><tr><td align="left"><bold>wt/wt</bold></td><td align="center">503 (78.0)</td><td align="center">671 (80.3)</td><td align="center">1.15 (0.89&#x02013;1.48)</td><td align="center">0.28</td><td align="center">419 (81.4)</td><td align="center">1.23 (0.92&#x02013;1.64)</td><td align="center">0.16</td></tr><tr><td align="left"><bold>CCR5 allele</bold></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold>&#x00394;32</bold></td><td align="center">148 (11.5)</td><td align="center">174 (10.4)</td><td align="center">0.90 (0.71&#x02013;1.13)</td><td align="center">0.35</td><td align="center">99 (9.7)</td><td align="center">0.82 (0.63&#x02013;1.07)</td><td align="center">0.15</td></tr><tr><td align="left"><bold>wt</bold></td><td align="center">1142 (88.5)</td><td align="center">1498 (89.6)</td><td></td><td></td><td align="center">931 (90.4)</td><td></td><td></td></tr></tbody></table><table-wrap-foot><p>RA: rheumatoid arthritis; JIA: juvenile idiopathic arthritis; N: number of individuals/chromosomes with the denoted genotype/allele; OR (95% CI): Odds ratio with corresponding 95% confidence interval; wt: wild type; &#x00394;32: 32 bp deletion.</p></table-wrap-foot></table-wrap><p>Our results, from the largest cohort of RA patients and controls investigated to date, do not support the existence of a negative association between <italic>CCR5&#x00394;32 </italic>and disease (OR = 0.90; 95% CI [0.71&#x02013;1.14]). Neither was the proposed disease resistance provided by homozygosity of the deletion sustained in our data set. The frequency of <italic>CCR5&#x00394;32 </italic>in our control population is in the same range as that observed in other European populations and is highly similar to that reported in a Danish population [<xref ref-type="bibr" rid="B11">11</xref>]. <italic>CCR5&#x00394;32 </italic>has been found to have its highest prevalence among Nordic populations [<xref ref-type="bibr" rid="B9">9</xref>], which from a statistical power perspective should favour detection of a negative association in our Norwegian cohort, on the other hand deviating results between populations for disease associated alleles is not uncommon, e.g. for <italic>PADI4 </italic>[<xref ref-type="bibr" rid="B22">22</xref>-<xref ref-type="bibr" rid="B25">25</xref>].</p><p>Altogether, two studies suggest an association between <italic>CCR5&#x00394;32 </italic>and RA [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>], while three studies [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B12">12</xref>], in addition to ours, do not reveal statistical significant evidence to support this. The number of patients included in the positive studies was 160 and 516 whereas in the negative studies 278, 163, 673 and 853 patients were analysed. A weak effect of <italic>CCR5&#x00394;32 </italic>on the disease risk, combined with inadequate power, could explain the contradictory results. Alternatively, there could be true differences between the populations in the effect exercised by <italic>CCR5</italic>; i.e. due to genetic or allelic heterogeneity, variable influence of environmental factors, gene-gene interaction, or variable linkage disequilibrium patterns. All studies display a deviation in the direction of a lower frequency for the deletion among RA patients, but in our data set only a 0.9% reduction in frequency was seen in RA patients compared to controls. The results of a recent meta-analysis of pooled cases and controls were in favour of a negative association (OR = 0.65 (95% CI [0.55&#x02013;0.77])). [<xref ref-type="bibr" rid="B17">17</xref>]. We recalculated the power of our RA study post hoc based on the odds ratio for the <italic>CCR5&#x00394;32 </italic>obtained in the recent meta-analysis [<xref ref-type="bibr" rid="B17">17</xref>], and given this risk effect our power was reduced to 63%. When our RA data set was included in a revised meta-analysis, the overall risk estimate was greatly reduced (OR = 0.83; 95% CI [0.73&#x02013;0.95, <italic>p </italic>= 0.0068]). Furthermore, if the true risk estimate is in the range of that calculated after also including our data into the pooled meta-analysis, one would need almost 4000 cases and an equal amount of controls to replicate the finding with an 80% power. Notably, the <italic>CCR5&#x00394;32 </italic>meta-analysis may also have been prone to type 1 error caused by e.g. publication bias or heterogeneity between the populations included in the combined analysis [<xref ref-type="bibr" rid="B26">26</xref>].</p><p>Our data does not reveal an association in JIA. After the initiation of our study, the possible association of <italic>CCR5 </italic>in JIA was addressed, and the authors reported a negative association between <italic>CCR5&#x00394;32 </italic>and childhood arthritis, particularly in the early onset group and in those diagnosed with pauciarticular subtype [<xref ref-type="bibr" rid="B15">15</xref>]. This finding was not sustained in our data set as no association was revealed when stratifying for either JIA subgroups, including the oligoarthirits patients (comparable to the pauciarticular group defined by the ACR criterias; OR = 0.80, 95% CI [0.54&#x02013;1.17], <italic>p </italic>= 0.23), or early disease onset (&#x0003c;6 years; OR = 0.81, 95% CI [0.55&#x02013;1.19], <italic>p </italic>= 0.27). Further investigations are warranted for JIA before any firm conclusions can be drawn. Nevertheless, our study does not suggest that <italic>CCR5&#x00394;32 </italic>influences the risk of JIA, and if present the effect is likely to be small.</p><p>CCR5 has functionally been implicated in RA, and our study does not formally exclude <italic>CCR5 </italic>as a candidate gene for RA and JIA. Polymorphisms located elsewhere in the gene could potentially be predisposing, and if the associations observed for &#x00394;32 is only secondary due to linkage disequilibrium, that could be an explanation for the discrepant results obtained by different studies. Interestingly, in the recently reported childhood arthritis study [<xref ref-type="bibr" rid="B15">15</xref>] other polymorphisms in the <italic>CCR5 </italic>gene were also investigated, and an additional association with the CCR5 -1835T allele was also observed. No strong linkage disequilibrium between <italic>CCR5&#x00394;32 </italic>and -1835T was evident, but the haplotype lacking both these alleles displayed positive association, which could suggest that the true etiological variant of <italic>CCR5 </italic>in RA or JIA pathogenesis that is still unidentified.</p></sec><sec><title>Conclusion</title><p>In conclusion, whether the <italic>CCR5 </italic>gene is involved in RA or JIA susceptibility remains unclear, however, our study suggests that if a protective effect is exercised by CCR5<italic>&#x00394;32</italic>, it is minor and less than predicted from the meta-analysis of previous publications[<xref ref-type="bibr" rid="B17">17</xref>].</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>EL and GBNN participated in the design of the study, performed the genotyping, statistical analysis and drafted the manuscript. EM participated in the design of the study and performed the genotyping of a part of the control material. BF, AMS and &#x000d8;TF contributed with DNA samples and clinical information for the JIA patients. TKK contributed with DNA samples and clinical information for the RA patients. ET helped writing the manuscript. BAL participated in the design of the study, statistical analysis and drafted the manuscript. All authors have read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/8/33/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work was funded by Rikshospitalet, Southern Norway Regional Health Authority, The Norwegian Women's Health Association and the Norwegian Foundation for Health and Rehabilitation. We thank the Norwegian Bone Marrow Donor Registry for making the control material available and Tom H. Karlsen for valuable input to the study.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pharoah</surname><given-names>DS</given-names></name><name><surname>Varsani</surname><given-names>H</given-names></name><name><surname>Tatham</surname><given-names>RW</given-names></name><name><surname>Newton</surname><given-names>KR</given-names></name><name><surname>de</surname><given-names>JW</given-names></name><name><surname>Prakken</surname><given-names>BJ</given-names></name><name><surname>Klein</surname><given-names>N</given-names></name><name><surname>Wedderburn</surname><given-names>LR</given-names></name></person-group><article-title>Expression of the inflammatory chemokines CCL5, CCL3 and CXCL10 in juvenile idiopathic arthritis, and demonstration of CCL5 production by an atypical subset of CD8+ T cells</article-title><source>Arthritis Res Ther</source><year>2006</year><volume>8</volume><fpage>R50</fpage><pub-id pub-id-type="pmid">16507178</pub-id><pub-id pub-id-type="doi">10.1186/ar1913</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Szekanecz</surname><given-names>Z</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Koch</surname><given-names>AE</given-names></name></person-group><article-title>Chemokines and chemokine receptors in rheumatoid arthritis</article-title><source>Semin Immunol</source><year>2003</year><volume>15</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">12495637</pub-id><pub-id pub-id-type="doi">10.1016/S1044-5323(02)00124-0</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>LaRosa</surname><given-names>G</given-names></name><name><surname>Kassam</surname><given-names>N</given-names></name><name><surname>Gordon</surname><given-names>CJ</given-names></name><name><surname>Heath</surname><given-names>H</given-names></name><name><surname>Ruffing</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Humblias</surname><given-names>J</given-names></name><name><surname>Samson</surname><given-names>M</given-names></name><name><surname>Parmentier</surname><given-names>M</given-names></name><name><surname>Moore</surname><given-names>JP</given-names></name><name><surname>Mackay</surname><given-names>CR</given-names></name></person-group><article-title>Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding</article-title><source>J Exp Med</source><year>1997</year><volume>186</volume><fpage>1373</fpage><lpage>1381</lpage><pub-id pub-id-type="pmid">9334377</pub-id><pub-id pub-id-type="doi">10.1084/jem.186.8.1373</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wedderburn</surname><given-names>LR</given-names></name><name><surname>Robinson</surname><given-names>N</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Varsani</surname><given-names>H</given-names></name><name><surname>Woo</surname><given-names>P</given-names></name></person-group><article-title>Selective recruitment of polarized T cells expressing CCR5 and CXCR3 to the inflamed joints of children with juvenile idiopathic arthritis</article-title><source>Arthritis Rheum</source><year>2000</year><volume>43</volume><fpage>765</fpage><lpage>774</lpage><pub-id pub-id-type="pmid">10765921</pub-id><pub-id pub-id-type="doi">10.1002/1529-0131(200004)43:4&#x0003c;765::AID-ANR7&#x0003e;3.0.CO;2-B</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>N</given-names></name><name><surname>Nakajima</surname><given-names>A</given-names></name><name><surname>Yoshino</surname><given-names>S</given-names></name><name><surname>Matsushima</surname><given-names>K</given-names></name><name><surname>Yagita</surname><given-names>H</given-names></name><name><surname>Okumura</surname><given-names>K</given-names></name></person-group><article-title>Selective accumulation of CCR5+ T lymphocytes into inflamed joints of rheumatoid arthritis</article-title><source>Int Immunol</source><year>1999</year><volume>11</volume><fpage>553</fpage><lpage>559</lpage><pub-id pub-id-type="pmid">10323208</pub-id><pub-id pub-id-type="doi">10.1093/intimm/11.4.553</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Samson</surname><given-names>M</given-names></name><name><surname>Soularue</surname><given-names>P</given-names></name><name><surname>Vassart</surname><given-names>G</given-names></name><name><surname>Parmentier</surname><given-names>M</given-names></name></person-group><article-title>The genes encoding the human CC-chemokine receptors CC-CKR1 to CC-CKR5 (CMKBR1-CMKBR5) are clustered in the p21.3-p24 region of chromosome 3</article-title><source>Genomics</source><year>1996</year><volume>36</volume><fpage>522</fpage><lpage>526</lpage><pub-id pub-id-type="pmid">8884276</pub-id><pub-id pub-id-type="doi">10.1006/geno.1996.0498</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Venkatesan</surname><given-names>S</given-names></name><name><surname>Petrovic</surname><given-names>A</given-names></name><name><surname>Van Ryk</surname><given-names>DI</given-names></name><name><surname>Locati</surname><given-names>M</given-names></name><name><surname>Weissman</surname><given-names>D</given-names></name><name><surname>Murphy</surname><given-names>PM</given-names></name></person-group><article-title>Reduced cell surface expression of CCR5 in CCR5Delta 32 heterozygotes is mediated by gene dosage, rather than by receptor sequestration</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>2287</fpage><lpage>2301</lpage><pub-id pub-id-type="pmid">11604406</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M108321200</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benkirane</surname><given-names>M</given-names></name><name><surname>Jin</surname><given-names>DY</given-names></name><name><surname>Chun</surname><given-names>RF</given-names></name><name><surname>Koup</surname><given-names>RA</given-names></name><name><surname>Jeang</surname><given-names>KT</given-names></name></person-group><article-title>Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><fpage>30603</fpage><lpage>30606</lpage><pub-id pub-id-type="pmid">9388191</pub-id><pub-id pub-id-type="doi">10.1074/jbc.272.49.30603</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lucotte</surname><given-names>G</given-names></name></person-group><article-title>Distribution of the CCR5 gene 32-basepair deletion in West Europe. A hypothesis about the possible dispersion of the mutation by the Vikings in historical times</article-title><source>Hum Immunol</source><year>2001</year><volume>62</volume><fpage>933</fpage><lpage>936</lpage><pub-id pub-id-type="pmid">11543895</pub-id><pub-id pub-id-type="doi">10.1016/S0198-8859(01)00292-0</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cooke</surname><given-names>SP</given-names></name><name><surname>Forrest</surname><given-names>G</given-names></name><name><surname>Venables</surname><given-names>PJ</given-names></name><name><surname>Hajeer</surname><given-names>A</given-names></name></person-group><article-title>The delta32 deletion of CCR5 receptor in rheumatoid arthritis</article-title><source>Arthritis Rheum</source><year>1998</year><volume>41</volume><fpage>1135</fpage><lpage>1136</lpage><pub-id pub-id-type="pmid">9627027</pub-id><pub-id pub-id-type="doi">10.1002/1529-0131(199806)41:6&#x0003c;1135::AID-ART24&#x0003e;3.0.CO;2-N</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garred</surname><given-names>P</given-names></name><name><surname>Madsen</surname><given-names>HO</given-names></name><name><surname>Petersen</surname><given-names>J</given-names></name><name><surname>Marquart</surname><given-names>H</given-names></name><name><surname>Hansen</surname><given-names>TM</given-names></name><name><surname>Freiesleben</surname><given-names>SS</given-names></name><name><surname>Volck</surname><given-names>B</given-names></name><name><surname>Svejgaard</surname><given-names>A</given-names></name><name><surname>Andersen</surname><given-names>V</given-names></name></person-group><article-title>CC chemokine receptor 5 polymorphism in rheumatoid arthritis</article-title><source>J Rheumatol</source><year>1998</year><volume>25</volume><fpage>1462</fpage><lpage>1465</lpage><pub-id pub-id-type="pmid">9712084</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Reino</surname><given-names>JJ</given-names></name><name><surname>Pablos</surname><given-names>JL</given-names></name><name><surname>Carreira</surname><given-names>PE</given-names></name><name><surname>Santiago</surname><given-names>B</given-names></name><name><surname>Serrano</surname><given-names>L</given-names></name><name><surname>Vicario</surname><given-names>JL</given-names></name><name><surname>Balsa</surname><given-names>A</given-names></name><name><surname>Figueroa</surname><given-names>M</given-names></name><name><surname>de</surname><given-names>J</given-names><suffix>M.D.</suffix></name></person-group><article-title>Association of rheumatoid arthritis with a functional chemokine receptor, CCR5</article-title><source>Arthritis Rheum</source><year>1999</year><volume>42</volume><fpage>989</fpage><lpage>992</lpage><pub-id pub-id-type="pmid">10323455</pub-id><pub-id pub-id-type="doi">10.1002/1529-0131(199905)42:5&#x0003c;989::AID-ANR18&#x0003e;3.0.CO;2-U</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pokorny</surname><given-names>V</given-names></name><name><surname>McQueen</surname><given-names>F</given-names></name><name><surname>Yeoman</surname><given-names>S</given-names></name><name><surname>Merriman</surname><given-names>M</given-names></name><name><surname>Merriman</surname><given-names>A</given-names></name><name><surname>Harrison</surname><given-names>A</given-names></name><name><surname>Highton</surname><given-names>J</given-names></name><name><surname>McLean</surname><given-names>L</given-names></name></person-group><article-title>Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis</article-title><source>Ann Rheum Dis</source><year>2005</year><volume>64</volume><fpage>487</fpage><lpage>490</lpage><pub-id pub-id-type="pmid">15331395</pub-id><pub-id pub-id-type="doi">10.1136/ard.2004.023333</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zapico</surname><given-names>I</given-names></name><name><surname>Coto</surname><given-names>E</given-names></name><name><surname>Rodriguez</surname><given-names>A</given-names></name><name><surname>Alvarez</surname><given-names>C</given-names></name><name><surname>Torre</surname><given-names>JC</given-names></name><name><surname>Alvarez</surname><given-names>V</given-names></name></person-group><article-title>CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis</article-title><source>Genes Immun</source><year>2000</year><volume>1</volume><fpage>288</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">11196706</pub-id><pub-id pub-id-type="doi">10.1038/sj.gene.6363673</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prahalad</surname><given-names>S</given-names></name><name><surname>Bohnsack</surname><given-names>JF</given-names></name><name><surname>Jorde</surname><given-names>LB</given-names></name><name><surname>Whiting</surname><given-names>A</given-names></name><name><surname>Clifford</surname><given-names>B</given-names></name><name><surname>Dunn</surname><given-names>D</given-names></name><name><surname>Weiss</surname><given-names>R</given-names></name><name><surname>Moroldo</surname><given-names>M</given-names></name><name><surname>Thompson</surname><given-names>SD</given-names></name><name><surname>Glass</surname><given-names>DN</given-names></name><name><surname>Bamshad</surname><given-names>MJ</given-names></name></person-group><article-title>Association of two functional polymorphisms in the CCR5 gene with juvenile rheumatoid arthritis</article-title><source>Genes Immun</source><year>2006</year><volume>7</volume><fpage>468</fpage><lpage>475</lpage><pub-id pub-id-type="pmid">16775617</pub-id><pub-id pub-id-type="doi">10.1038/sj.gene.6364317</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>John</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>S</given-names></name><name><surname>Morrison</surname><given-names>JF</given-names></name><name><surname>Symmons</surname><given-names>D</given-names></name><name><surname>Worthington</surname><given-names>J</given-names></name><name><surname>Silman</surname><given-names>A</given-names></name><name><surname>Barton</surname><given-names>A</given-names></name></person-group><article-title>Genetic variation in CCR5 does not predict clinical outcome in inflammatory arthritis</article-title><source>Arthritis Rheum</source><year>2003</year><volume>48</volume><fpage>3615</fpage><lpage>3616</lpage><pub-id pub-id-type="pmid">14674019</pub-id><pub-id pub-id-type="doi">10.1002/art.11360</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prahalad</surname><given-names>S</given-names></name></person-group><article-title>Negative association between the chemokine receptor CCR5-Delta32 polymorphism and rheumatoid arthritis: a meta-analysis</article-title><source>Genes Immun</source><year>2006</year><volume>7</volume><fpage>264</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">16541097</pub-id><pub-id pub-id-type="doi">10.1038/sj.gene.6364298</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arnett</surname><given-names>FC</given-names></name><name><surname>Edworthy</surname><given-names>SM</given-names></name><name><surname>Bloch</surname><given-names>DA</given-names></name><name><surname>McShane</surname><given-names>DJ</given-names></name><name><surname>Fries</surname><given-names>JF</given-names></name><name><surname>Cooper</surname><given-names>NS</given-names></name><name><surname>Healey</surname><given-names>LA</given-names></name><name><surname>Kaplan</surname><given-names>SR</given-names></name><name><surname>Liang</surname><given-names>MH</given-names></name><name><surname>Luthra</surname><given-names>HS</given-names></name><collab>.</collab></person-group><article-title>The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis</article-title><source>Arthritis Rheum</source><year>1988</year><volume>31</volume><fpage>315</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">3358796</pub-id><pub-id pub-id-type="doi">10.1002/art.1780310302</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Petty</surname><given-names>RE</given-names></name><name><surname>Southwood</surname><given-names>TR</given-names></name><name><surname>Manners</surname><given-names>P</given-names></name><name><surname>Baum</surname><given-names>J</given-names></name><name><surname>Glass</surname><given-names>DN</given-names></name><name><surname>Goldenberg</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Maldonado-Cocco</surname><given-names>J</given-names></name><name><surname>Orozco-Alcala</surname><given-names>J</given-names></name><name><surname>Prieur</surname><given-names>AM</given-names></name><name><surname>Suarez-Almazor</surname><given-names>ME</given-names></name><name><surname>Woo</surname><given-names>P</given-names></name></person-group><article-title>International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001</article-title><source>J Rheumatol</source><year>2004</year><volume>31</volume><fpage>390</fpage><lpage>392</lpage><pub-id pub-id-type="pmid">14760812</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Melum</surname><given-names>E</given-names></name><name><surname>Karlsen</surname><given-names>TH</given-names></name><name><surname>Broome</surname><given-names>U</given-names></name><name><surname>Thorsby</surname><given-names>E</given-names></name><name><surname>Schrumpf</surname><given-names>E</given-names></name><name><surname>Boberg</surname><given-names>KM</given-names></name><name><surname>Lie</surname><given-names>BA</given-names></name></person-group><article-title>The 32-base pair deletion of the chemokine receptor 5 gene (CCR5-Delta32) is not associated with primary sclerosing cholangitis in 363 Scandinavian patients</article-title><source>Tissue Antigens</source><year>2006</year><volume>68</volume><fpage>78</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">16774544</pub-id><pub-id pub-id-type="doi">10.1111/j.1399-0039.2006.00604.x</pub-id></citation></ref><ref id="B21"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Calculator</surname><given-names>P</given-names></name></person-group><year>2007</year><ext-link ext-link-type="uri" xlink:href="http://calculators.stat.ucla.edu/powercalc/"/></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barton</surname><given-names>A</given-names></name><name><surname>Bowes</surname><given-names>J</given-names></name><name><surname>Eyre</surname><given-names>S</given-names></name><name><surname>Spreckley</surname><given-names>K</given-names></name><name><surname>Hinks</surname><given-names>A</given-names></name><name><surname>John</surname><given-names>S</given-names></name><name><surname>Worthington</surname><given-names>J</given-names></name></person-group><article-title>A functional haplotype of the PADI4 gene associated with rheumatoid arthritis in a Japanese population is not associated in a United Kingdom population</article-title><source>Arthritis Rheum</source><year>2004</year><volume>50</volume><fpage>1117</fpage><lpage>1121</lpage><pub-id pub-id-type="pmid">15077293</pub-id><pub-id pub-id-type="doi">10.1002/art.20169</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>A</given-names></name><name><surname>Valdivia</surname><given-names>A</given-names></name><name><surname>Pascual-Salcedo</surname><given-names>D</given-names></name><name><surname>Lamas</surname><given-names>JR</given-names></name><name><surname>Fernandez-Arquero</surname><given-names>M</given-names></name><name><surname>Balsa</surname><given-names>A</given-names></name><name><surname>Fernandez-Gutierrez</surname><given-names>B</given-names></name><name><surname>de la Concha</surname><given-names>EG</given-names></name><name><surname>Urcelay</surname><given-names>E</given-names></name></person-group><article-title>PADI4 polymorphisms are not associated with rheumatoid arthritis in the Spanish population</article-title><source>Rheumatology (Oxford)</source><year>2005</year><volume>44</volume><fpage>1263</fpage><lpage>1266</lpage><pub-id pub-id-type="pmid">15998632</pub-id><pub-id pub-id-type="doi">10.1093/rheumatology/kei008</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Plenge</surname><given-names>RM</given-names></name><name><surname>Padyukov</surname><given-names>L</given-names></name><name><surname>Remmers</surname><given-names>EF</given-names></name><name><surname>Purcell</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>AT</given-names></name><name><surname>Karlson</surname><given-names>EW</given-names></name><name><surname>Wolfe</surname><given-names>F</given-names></name><name><surname>Kastner</surname><given-names>DL</given-names></name><name><surname>Alfredsson</surname><given-names>L</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Gregersen</surname><given-names>PK</given-names></name><name><surname>Klareskog</surname><given-names>L</given-names></name><name><surname>Rioux</surname><given-names>JD</given-names></name></person-group><article-title>Replication of putative candidate-gene associations with rheumatoid arthritis in &#x0003e;4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4</article-title><source>Am J Hum Genet</source><year>2005</year><volume>77</volume><fpage>1044</fpage><lpage>1060</lpage><pub-id pub-id-type="pmid">16380915</pub-id><pub-id pub-id-type="doi">10.1086/498651</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>A</given-names></name><name><surname>Yamada</surname><given-names>R</given-names></name><name><surname>Chang</surname><given-names>X</given-names></name><name><surname>Tokuhiro</surname><given-names>S</given-names></name><name><surname>Sawada</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Nagasaki</surname><given-names>M</given-names></name><name><surname>Nakayama-Hamada</surname><given-names>M</given-names></name><name><surname>Kawaida</surname><given-names>R</given-names></name><name><surname>Ono</surname><given-names>M</given-names></name><name><surname>Ohtsuki</surname><given-names>M</given-names></name><name><surname>Furukawa</surname><given-names>H</given-names></name><name><surname>Yoshino</surname><given-names>S</given-names></name><name><surname>Yukioka</surname><given-names>M</given-names></name><name><surname>Tohma</surname><given-names>S</given-names></name><name><surname>Matsubara</surname><given-names>T</given-names></name><name><surname>Wakitani</surname><given-names>S</given-names></name><name><surname>Teshima</surname><given-names>R</given-names></name><name><surname>Nishioka</surname><given-names>Y</given-names></name><name><surname>Sekine</surname><given-names>A</given-names></name><name><surname>Iida</surname><given-names>A</given-names></name><name><surname>Takahashi</surname><given-names>A</given-names></name><name><surname>Tsunoda</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name></person-group><article-title>Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis</article-title><source>Nat Genet</source><year>2003</year><volume>34</volume><fpage>395</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">12833157</pub-id><pub-id pub-id-type="doi">10.1038/ng1206</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salanti</surname><given-names>G</given-names></name><name><surname>Sanderson</surname><given-names>S</given-names></name><name><surname>Higgins</surname><given-names>JP</given-names></name></person-group><article-title>Obstacles and opportunities in meta-analysis of genetic association studies</article-title><source>Genet Med</source><year>2005</year><volume>7</volume><fpage>13</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">15654223</pub-id></citation></ref></ref-list></back></article> 